Bullish
Humana Inc. stock has reached a new 52-week high of $361.21, significantly above its previous high of $356.01, reflecting a 55.47% increase over the p...
Bullish
Humana Inc. (NYSE: HUM) stock has hit a new 52-week high of $361.21, trading just 1% above its previous high of $356.01, with a market capitalization ...
Mizuho Securities has reiterated its Buy rating for Humana (HUM.US) and increased its price target to $390. This adjustment reflects the firm's contin...
/Humana%20Inc_%20logo%20on%20building-by%20BalkansCat%20via%20iStock.jpg)
Bullish
Humana Inc. (HUM) has significantly outperformed the Nasdaq Composite ($NASX) over the past three months and the past 52 weeks, demonstrating strong g...
Bullish
Humana (HUM) saw a significant stock increase of 14.6% due to positive trends in medical utilization and reduced regulatory pressures in the healthcar...
Bullish
Humana (HUM) stock surged 6% as health insurance stocks rallied, driven by analyst optimism regarding moderating medical costs and the potential for A...
Neutral
This article identifies four healthcare stocks (Humana, Novo Nordisk, Pfizer, and UnitedHealth Group) that experienced "whale alerts" — significant op...
Bullish
Health insurance stocks, including Humana, UnitedHealth, and Cigna, saw significant gains due to bullish analyst reports. These reports highlight mode...
Humana Inc.'s average 12-month price target has been increased to $283.54 by 24 analysts, up from $279.17. This new target implies a potential 13% dow...
Bullish
Humana Inc. saw its stock surge by 6.7% to $349.58 on Thursday, participating in a broad rally that impacted healthcare plan stocks across the sector....
Bernstein has increased its price target for Humana (HUM) to $425 from $288, while reiterating an Outperform rating on the stock. This adjustment refl...
The article highlights that CVRx's Barostim device is well-positioned to address a significant unmet need in heart failure, backed by strong clinical ...
Bullish
Humana Inc. has filed a Form 8-K with the SEC, reaffirming its earnings guidance for the full year 2026, with diluted EPS at least $8.36 and adjusted ...
Neutral
RBC Capital has reaffirmed its Sector Perform rating and $246.00 price target for Humana Inc. after the company reiterated its fiscal 2026 adjusted EP...
Humana (HUM) surged 8.1% to $330.22, significantly outperforming peers Centene (CNC) and Molina Healthcare (MOH) within a sector-wide rally for health...
Bullish
Humana Inc. (NYSE: HUM) stock has reached a new 52-week high of $318.55, driven by strong earnings, strategic initiatives, and analyst upgrades. The h...
Neutral
Humana Inc. (NYSE: HUM) stock reached a new 52-week high of $318.55, reflecting a significant 33% surge over the past year. This performance is attrib...
Bullish
Humana Inc. (HUM) has reaffirmed its 2026 earnings guidance, projecting a minimum of $8.36 in diluted EPS and at least $9.00 in adjusted EPS. This gui...
Humana Inc. has reaffirmed its financial guidance for fiscal year 2026, anticipating an adjusted earnings per share of at least $9. This guidance alig...
Bullish
Humana Inc. plans to reaffirm its fiscal year 2026 earnings guidance of at least $8.36 in diluted EPS and $9.00 in adjusted EPS during investor meetin...